Payment overview · 2025
General Payments
$254.69
12 reported records · 8 companies
Healthcare provider profile · identity verified
Anitha Bhat, MD
Allopathic & Osteopathic Physicians|Internal Medicine · APPLE VALLEY, CA · NPI 1639480585
Verified facts
What the public records show
CMS Open Payments records show Anitha Bhat, MD received $254.69 in general payments during 2025 across 12 reported records.
Abbott Laboratories accounted for 23.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Kerendia, Mounjaro.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Kerendia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $60.69 | 23.8% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $54.06 | 21.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $44.60 | 17.5% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $27.55 | 10.8% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.28 | 8.4% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $15.95 | 6.3% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.37 | 6.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.19 | 6.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $254.69 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $60.69 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $54.06 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $44.60 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $27.55 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $27.55 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $27.55 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $21.28 | 1 | 2025 |
Source payment records
|
|||||
| Respiratory Normalized: respiratory |
Device | Philips North America LLC | $15.95 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.37 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Kerendia kerendia |
2025 | Kerendia | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
91 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
85 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 473 | 75 |
| Levothyroxine Sodium | Levothyroxine Sodium | 405 | 118 |
| Atorvastatin Calcium | Atorvastatin Calcium | 313 | 104 |
| Amlodipine Besylate | Amlodipine Besylate | 291 | 96 |
| Losartan Potassium | Losartan Potassium | 270 | 82 |
| Gabapentin | Gabapentin | 263 | 82 |
| Lisinopril | Lisinopril | 228 | 76 |
| Metformin Hcl | Metformin Hcl | 212 | 74 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 192 | 73 |
| Simvastatin | Simvastatin | 192 | 61 |
| Trazodone Hcl | Trazodone Hcl | 189 | 48 |
| Omeprazole | Omeprazole | 155 | 47 |
| Alprazolam | Alprazolam | 154 | 36 |
| Furosemide | Furosemide | 154 | 52 |
| Tramadol Hcl | Tramadol Hcl | 147 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 145 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 144 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 129 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 121 | 47 |
| Ibuprofen | Ibuprofen | 118 | 40 |
| Zolpidem Tartrate | Zolpidem Tartrate | 117 | 20 |
| Alendronate Sodium | Alendronate Sodium | 116 | 36 |
| Baclofen | Baclofen | 105 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 103 | 19 |
| Sertraline Hcl | Sertraline Hcl | 103 | 24 |
| Carvedilol | Carvedilol | 102 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 101 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 93 | 24 |
| Jardiance | Empagliflozin | 91 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 90 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 88 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 86 | 25 |
| Eliquis | Apixaban | 85 | 23 |
| Atenolol | Atenolol | 82 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 82 | 31 |
| Ozempic | Semaglutide | 82 | 15 |
| Potassium Chloride | Potassium Chloride | 81 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 79 | 18 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 76 | 28 |
| Finasteride | Finasteride | 75 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 75 | 21 |
| Famotidine | Famotidine | 73 | 29 |
| Nifedipine Er | Nifedipine | 72 | 26 |
| Glipizide | Glipizide | 63 | 20 |
| Montelukast Sodium | Montelukast Sodium | 63 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 58 | 19 |
| Azithromycin | Azithromycin | 57 | 49 |
| Oxycodone Hcl | Oxycodone Hcl | 57 | suppressed |
| Allopurinol | Allopurinol | 56 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 56 | 12 |
| Lorazepam | Lorazepam | 54 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 54 | 16 |
| Prednisone | Prednisone | 52 | 32 |
| Clonidine Hcl | Clonidine Hcl | 50 | 18 |
| Estradiol | Estradiol | 48 | 20 |
| Buspirone Hcl | Buspirone Hcl | 47 | 22 |
| Donepezil Hcl | Donepezil Hcl | 47 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 47 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 45 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 45 | 12 |
| Spironolactone | Spironolactone | 44 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 43 | 13 |
| Ezetimibe | Ezetimibe | 42 | 15 |
| Clonazepam | Clonazepam | 40 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 40 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 40 | 29 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 37 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | 11 |
| Nystatin | Nystatin | 36 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 35 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 35 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | 15 |
| Pregabalin | Pregabalin | 33 | suppressed |
| Lovastatin | Lovastatin | 32 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 27 |
| Fentanyl | Fentanyl | 31 | suppressed |
| Temazepam | Temazepam | 31 | suppressed |
| Ketoconazole | Ketoconazole | 30 | 12 |
| Midodrine Hcl | Midodrine Hcl | 30 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 30 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 21 |
| Lactulose | Lactulose | 29 | suppressed |
| Naproxen | Naproxen | 29 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 28 | 12 |
| Hydrocortisone | Hydrocortisone | 28 | 12 |
| Meloxicam | Meloxicam | 28 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Glipizide Er | Glipizide | 27 | suppressed |
| Creon | Lipase/Protease/Amylase | 26 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 25 | suppressed |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 18 |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Carisoprodol | Carisoprodol | 21 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 21 | suppressed |
| Fluconazole | Fluconazole | 20 | 13 |
| Liothyronine Sodium | Liothyronine Sodium | 20 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 19 | 16 |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Lubiprostone | Lubiprostone | 15 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Kerendia | Finerenone | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 11 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $254.69 · 12 records | Abbott Laboratories | ABRYSVO, COMIRNATY, Cologuard Collection Kit, FREESTYLE LIBRE 3, GVOKE HYPOPEN, Kerendia, MOUNJARO, PREVNAR 20, REXULTI, Respiratory | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Kerendia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Bayer Healthcare Pharmaceuticals Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error